| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DEFB110 |
| Uniprot No | Q30KQ9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-62aa |
| 氨基酸序列 | MKIQLFFFILHFWVTILPARSNFEPKYRFERCEKVRGICKTFCDDVEYDYGYCIKWRSQCCV |
| 分子量 | 33.77 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人DEFB109蛋白的3篇参考文献示例(注：部分文献为虚构示例，实际研究中请根据具体文献补充)：
---
1. **文献名称**：*Expression and Antimicrobial Characterization of Recombinant Human DEFB109 in a Prokaryotic System*
**作者**：Chen, L., et al.
**摘要**：研究通过原核表达系统(大肠杆菌)成功表达并纯化重组人DEFB109蛋白，验证其对革兰氏阴性菌(如大肠杆菌)和革兰氏阳性菌(如金黄色葡萄球菌)的广谱抗菌活性，并探讨其可能的抗菌机制。
2. **文献名称**：*Structural and Functional Analysis of Human DEFB109: Implications for Immunomodulatory Roles*
**作者**：Kim, S., et al.
**摘要**：通过圆二色光谱和分子动力学模拟解析重组DEFB109的二级结构，发现其通过TLR4/NF-κB通路调控巨噬细胞炎症因子分泌，提示其在先天免疫和自身免疫疾病中的潜在应用价值。
3. **文献名称**：*Recombinant DEFB109 Enhances Epithelial Barrier Function and Suppresses HSV-2 Infection In Vitro*
**作者**：Garcia, M., et al.
**摘要**：研究发现重组DEFB109可增强阴道上皮细胞屏障完整性，并通过直接结合病毒包膜抑制HSV-2的入侵，为开发基于防御素的抗病毒疗法提供依据。
---
**备注**：若需真实文献，建议查阅PubMed或Web of Science数据库，以关键词“recombinant DEFB109”或“human beta-defensin 109”检索近年研究。实际文献可能侧重表达优化、结构功能或疾病相关机制。
Recombinant human DEFB109 protein is a synthetically produced version of the endogenous beta-defensin 109 (DEFB109), a small cationic peptide belonging to the defensin family. Defensins are critical components of the innate immune system, known for their broad-spectrum antimicrobial activity against bacteria, fungi, and viruses. DEFB109. encoded by the *DEFB109* gene located on chromosome 8p23.1. is primarily expressed in epithelial tissues, such as the skin, respiratory tract, and urogenital system, where it contributes to mucosal immunity and microbial defense. Structurally, it features six conserved cysteine residues forming three disulfide bonds, stabilizing its characteristic β-sheet fold.
Recombinant DEFB109 is engineered using expression systems like *E. coli* or mammalian cells to ensure proper folding and post-translational modifications. Its production enables studies on immune regulation, host-pathogen interactions, and potential therapeutic applications. Research suggests DEFB109 not only disrupts microbial membranes via electrostatic interactions but also modulates immune cell activity, such as chemotaxis and cytokine production. Dysregulation of DEFB109 has been linked to inflammatory diseases and infections, highlighting its clinical relevance.
Current investigations focus on harnessing recombinant DEFB109 for antimicrobial therapies, wound healing, or as an immune adjuvant. Challenges include optimizing stability, minimizing cytotoxicity, and enhancing bioavailability. Its role in maintaining microbiome balance and combating antibiotic-resistant pathogens positions it as a promising candidate for biomedical innovation.
×
